Viropharma Inc

Viropharma — SLIDE PRESENTATION

54 slides from Viropharma's investor presentation, Jan 8, 2008

  1. Slide 1: Vancocin Bioequivalence (BE): Appropriate Method Development

    Exhibit 99.2 Vancocin® Bioequivalence (BE) Appropriate Method Development FDA Meeting January 7, 2008 1

  2. Slide 2: Vancocin

    Vancocin • Vancomycin Hydrochloride Capsules, USP • Contains chromatographically purified vancomycin hydrochloride, a tricyclic glycopeptide antibiotic derived from Amycolatopsis orientalis • Large molecule not absorbed across healthy gut – C66H75Cl2N9O24 •HCl MW 1486 • Available as 125 mg and 250 m

  3. Slide 3: Product Information

    Product Information • Manufacturing specifications developed empirically and incorporate a number of proprietary trade secrets • Indicated uses for Vancocin: “. . . for treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) and antibiotic- associated pse

  4. Slide 4: C. difficile Infection (CDI)

    C. difficile Infection (CDI) • Clostridium difficile is a spore-forming, gram-positive bacillus that produces exotoxins that are pathogenic to humans • C. difficile infection (CDI) ranges in severity from mild diarrhea to fulminant colitis and death • C. difficile exotoxins A and B cause colonic dys

  5. Slide 5: C. difficile Infection (CDI)

    C. difficile Infection (CDI) • An emerging public health epidemic – These rates have tripled since 2000 • Nosocomial and community acquired – Increase in cases without previous known antibiotic exposure • Reemerging hypervirulent strain associated with: – More severe disease – The epidemic strain pr

  6. Slide 6: C. difficile Infection (CDI)

    C. difficile Infection (CDI) • GI tract of CDI patients is not ‘normal’ or well understood • Wide range of motility • Fluid volume, pH, composition not well understood or characterized • Cellular changes in wall of the gut • Significantly different from the healthy gut 6

  7. Slide 7: Normal colon vs colon infected with Clostridium difficile

    * * * * * * “Normal” colon Colon infected with Clostridium difficile *************** ****** 7 *

  8. Slide 8: *

    * 8

  9. Slide 9: preety

    preety = ts i» 3% bas = ¢

  10. Slide 10: 10

    10

  11. Slide 11: Bioequivalence for Vancocin

    Bioequivalence for Vancocin • Historically, FDA required bioequivalence studies with clinical endpoints due to lack of any established alternative method • No public statement by OGD that it was considering changing its BE recommendation for this drug – In March 2006, third party announces OGD no lo

  12. Slide 12: Biopharmaceutics Classification System (BCS)

    Biopharmaceutics Classification System (BCS) • A drug development tool for identifying the contribution of three major factors, dissolution, solubility, and intestinal permeability, that govern the rate and extent of oral drug absorption from immediate release solid oral products (Amidon, 1998) • Ex

  13. Slide 13: BCS Guidance

    BCS Guidance • Issued in 2000 • Product of decade-long process – Participation of academia, industry, professional societies – Working groups, Advisory Committees, Conferences – Draft and final guidances • Included possibility of biowaiver for BCS-1 drugs 13

  14. Slide 14: BCS-Based Biowaiver

    BCS-Based Biowaiver • Intended for rapidly dissolving, highly soluble, highly permeable drugs • For use where dissolution > gastric emptying (dissolution not rate limiting to drug absorption) • Only a limited number of drug approvals have relied on BCS biowaiver 14

  15. Slide 15: BCS-Based Biowaiver

    BCS-Based Biowaiver • The BCS-based biowaiver has been available since 2000 • Expressed goal of many involved with developing and implementing the model is to expand the use of the waiver beyond BCS-1 drugs • To date, FDA has not determined that the waiver can be applied to other BCS classes 15

  16. Slide 16: BCS-Based Biowaiver

    BCS-Based Biowaiver • When applied to the intended products, FDA states that the risk of bioinequivalence associated with use of the waiver is minimal • FDA’s factors when evaluating risk of bioinequivalence – Likelihood of occurrence – Severity of consequences • FDA asserts two principles significa

  17. Slide 17: BCS-Based Biowaiver

    BCS-Based Biowaiver • It is not clear from public presentations or guidance that OGD incorporates the severity of consequences associated with bioinequivalence into its decision process • In contrast, biowaiver monographs developed for the WHO essential drugs include discussion of “Patient Risks Ass

  18. Slide 18: Considering Patient Risk When Determining Biowaiver Eligibility

    Considering Patient Risk When Determining Biowaiver Eligibility • Cimetidine – “has a wide therapeutic index and is not indicated for serious diseases. Therefore, even in the unlikely situation that a bioinequivalent drug product would pass . . . this would be unlikely to result in serious public he

  19. Slide 19: Considering Patient Risk When Determining Biowaiver Eligibility

    Considering Patient Risk When Determining Biowaiver Eligibility • Chloroquine – “When considering a biowaiver for a drug substance, its therapeutic index and indication also need to be taken into account. Chloroquine is indicated for serious diseases….In malaria therapy, resistant parasites are most

  20. Slide 20: How Does OGD Extrapolate BCS-Based Biowaiver to Vancocin?

    How Does OGD Extrapolate BCS- Based Biowaiver to Vancocin? • OGD states, without reference to supporting data, that Vancocin capsules are highly soluble and rapidly dissolving • Does OGD use the fact that vancomycin is not absorbed from the healthy gut as the basis for considering it a BCS-1 compoun

  21. Slide 21: Scientific Principles for BCS-Based Waivers

    Scientific Principles for BCS- Based Waivers • “If two drug products have the same in vivo dissolution profile under all luminal conditions, they will have the same rate and extent of availability at the site of action.” • “For locally GI acting drugs, . . . In vitro dissolution testing must cover t

  22. Slide 22: Concerns with In Vitro Test for Vancocin

    Concerns with In Vitro Test for Vancocin • Untested hypothesis • Consequences of bioinequivalence are severe • Available clinical data are not consistent with apparent underlying assumptions for in vitro test • Vancocin dissolution data do not support use of in vitro biowaiver • Safety concerns exis

  23. Slide 23: Untested Hypothesis

    Untested Hypothesis • Appropriateness of the in vitro method – Unclear as to the range of potential in vivo conditions found in patients receiving the drug • Relevant hydrodynamic conditions • Fluid volumes • Biorelevant dissolution media • Multi stage dissolution approach • FDA and outside experts

  24. Slide 24: Consequences of Bioinequivalence Are Severe

    Consequences of Bioinequivalence Are Severe • Apparent failure by OGD to consider consequences of bioinequivalence – Serious morbidity or death – Difficult to detect under clinical use conditions whether bioinequivalent vancomycin product contributed to treatment failure – OGD’s expressed position t

  25. Slide 25: Available Clinical Data Are Not Consistent With the Hypothesis

    Available Clinical Data Are Not Consistent With the Hypothesis Underlying Proposed Biowaiver for Vancomycin Capsules • FDA determined that the oral solution and Vancocin capsule were shown not to be the same • Early clinical development of teicoplanin, a glycopeptide similar to vancomycin, for treat

  26. Slide 26: Vancocin Dissolution Data Are Not Consistent with In Vitro Test

    Vancocin Dissolution Data Are Not Consistent with In Vitro Test • Data generated by ViroPharma and submitted to FDA do not support OGD’s statement that the RLD for oral vancomycin capsules is rapidly dissolving under all of the recommended test conditions – 250 mg capsules are not rapidly dissolving

  27. Slide 27: Safety Concerns Exist

    Safety Concerns Exist • Safety concerns with lack of in vivo testing – Administration of vancomycin capsules to patients can result in systemic absorption of therapeutically relevant levels of drug due to compromised GI tracts • Systemic toxicity has been associated with use of the oral capsule prod

  28. Slide 28: Bioequivalence for Antibiotics

    Bioequivalence for Antibiotics • Ensuring bioequivalence for generic antibiotics is critical for patient care – Unique concerns with antibiotics – Different from other classes of drugs • Bioequivalence method development for these agents requires the application of rigorous science and a transparent

  29. Slide 29: Bioequivalence for Vancocin

    Bioequivalence for Vancocin • The proposed in vitro dissolution test to establish BE for Vancocin is not appropriate – In vivo GI conditions in patients receiving the drug are unknown – Requires a new model that accounts for the biopharmaceutics of the drug in patients • Permeability is an important

  30. Slide 30: Open Method Development

    Open Method Development • Development of novel BE methods requires process and transparency – Importance of predictable open and transparent process – Need for advice and review from external stakeholders and scientific experts 30

  31. Slide 31: Pathway Forward

    Pathway Forward • There are 2 viable options to demonstrate BE for vancomycin capsules that ensure patient safety (1) Maintain clinical endpoint BE for vancomycin capsules (2) Appropriate method development of alternative to clinical testing 31

  32. Slide 32: Appropriate Method Development of Alternative to Clinical Testing

    Appropriate Method Development of Alternative to Clinical Testing • Extrapolation of BCS-based waivers to non-BCS drugs is a significant step – These agents represent different classes of drugs • Approach should be data-driven, not an untested hypothesis that relies on the application of ‘scientific

  33. Slide 33: Maintain Clinical Endpoint BE for Vancomycin Capsules

    Maintain Clinical Endpoint BE for Vancomycin Capsules • Clinical trials are the appropriate endpoint for this disease/drug given the current state of dissolution science • Clinical endpoint BE trials for vancomycin capsules can be designed • The fact that generic companies may not be capable or will

  34. Slide 34: Public Confidence & Generic Drugs

    Public Confidence & Generic Drugs • “Transparency is one of the Agency’s key goals. It is critical that our audience understand what we do, how we do what we do, and why we do something.” FDA Data Quality Guidelines, F.IV • “Methods for equivalence based on sound science build the confidence of heal

  35. Slide 35: OGD Has Not Been Up Front About New Vancocin BE Method

    OGD Has Not Been Up Front About New Vancocin BE Method • Adopted without public notice or opportunity for comment • To date, no official notice of new method (some 2 yrs after revelation by 3d party) • To date, no notice of any data or rationale believed to support new method – despite 3/06 FOIA req

  36. Slide 36: Confidence Has Suffered

    Confidence Has Suffered • Among experts, e.g., “[T]here is considerable room for concern that generic vancomycin may not offer therapeutic equivalence.” Dr. William Bishai, Johns Hopkins, 8/06 • Among consumers, e.g., “I am concerned that removing the requirement for clinical trials before approving

  37. Slide 37: Confidence Has Suffered

    Confidence Has Suffered • On Capitol Hill, e.g.: “[W]e have agreed to engage with FDA through the oversight function of the HELP Committee to ensure that the scientific standards and procedures used in establishing bioequivalence for this life-threatening antibiotic are appropriate.” Senator Orrin H

  38. Slide 38: Potential OGD Responses

    Potential OGD Responses • Secrecy is OK because OGD has experts • No particular public process is required when adopting BE methods • Trade secret confidentiality prevents disclosure of new methods/data/rationale if they come from a generic applicant • ViroPharma’s petition = sufficient process 38

  39. Slide 39: The Risk of Secrecy

    The Risk of Secrecy • OGD Might Get it Wrong • Outside review enables better decisions, helps prevent mistakes reaching patients (e.g., DPK) • “FDA recognizes that public access to high quality information is critical to achieving [FDA’s mission to promote and protect the public health] and public i

  40. Slide 40: Credibility of OGD Expertise

    Credibility of OGD Expertise • MDS Pharma Audits: leaving 140 generic drugs on market despite “serious questions” about the validity of their BE data; refusing Congressional request to publicly identify the 140 drugs • Wellbutrin XL: return of depressive symptoms seen with generic versions, independ

  41. Slide 41: Public Process IS Required

    Public Process IS Required • FDA said as much when writing the bioequivalence regulations 30 years ago: “The Commissioner believes it is inconsistent with due process to issue a proposed bioequivalence requirement on the basis of ‘secret data and information’ that interested persons can neither see

  42. Slide 42: Public Process IS Required

    Public Process IS Required • Disclosure of record of OGD’s adoption of new method was required by April, 2006. 5 USC 552(a)(3) • Failure to index, make available/publish prevents use of new method to review or approve ANDAs. 5 USC 552(a)(2) • Failure to explain new method invalidates it. 5 USC 706(2

  43. Slide 43: Public Process IS Required

    Public Process IS Required • Notice-and-comment rulemaking required when FDA significantly changes regulatory interpretation. See, e.g., Alaska Hunters, 177 F.3d 1030, 1034 – Not a significant change to apply established science, e.g., blood PK for systemically acting products – Clearly a significan

  44. Slide 44: Trade Secrets Not An Issue Here

    Trade Secrets Not An Issue Here • OGD disseminated in vitro method to multiple private parties in early 2006 = no longer a trade secret, if it ever was • Dr. Yu stated 5/06 that OGD (not a private entity) had generated “lots of data” supporting new in vitro method = was never a trade secret in the f

  45. Slide 45: Selective Disclosure of New BE Methods Violates the Law

    Selective Disclosure of New BE Methods Violates the Law • OGD only disseminated new in vitro BE test to selected parties; no general public announcement made to date • Administrative Procedure Act, 5 USC 706(2)(A), violated when similarly situated parties treated differently, i.e., selective disclos

  46. Slide 46: Petition Not A Substitute for Appropriate Process

    Petition Not A Substitute for Appropriate Process • OGD triggered this petition by changing BE methods for Vancocin in the absence of public process • OGD-triggered petitions not a substitute for open BE method development – Absent notice of proposed method change, petitions unlikely to be filed in

  47. Slide 47: Petitions Asking to End Secrecy Become New Reason for Secrecy

    Petitions Asking to End Secrecy Become New Reason for Secrecy • No OGD intent to announce new method publicly • Stock analyst announces new OGD policy • Despite 3d party revelation, OGD refuses to disclose new method to ViroPharma, claiming it is confidential • ViroPharma forced to file petition in

  48. Slide 48: Recent Colazal Petition Response: Why Vancocin is Different

    Recent Colazal Petition Response Why Vancocin is Different • Bioinequivalence risk higher with Vancocin (serious morbidity/death) than with Colazal (unresolved ulcerative colitis) • OGD relied on PK for Colazal, but PK is unavailable for Vancocin • Unlike Colazal, data submitted to FDA contradict ke

  49. Slide 49: Colazal: Some Public Process

    Colazal: Some Public Process • Unlike Vancocin, there was some public process re alternatives to clinical endpoint BE studies for Colazal’s active moiety – discussion at 10/04 ACPS, data developed on other mesalamine formulations and discussed at various meetings • Nonetheless, OGD states non-public

  50. Slide 50: Colazal is Inconsistent with Open Process

    Colazal is Inconsistent with Open Process • Assertion that absence of public process remains an option contradicts May 2007 Guidance promise of opportunity to comment before final adoption of new BE methods: – “Product-specific BE recommendations will be developed and posted on the Internet… to faci

  51. Slide 51: Uncited Assertions in Colazal Response Inconsistent With Law

    Uncited Assertions in Colazal Response Inconsistent With Law • Colazal response cites no caselaw, and does not seek to support its assertion that non-public BE method development is a legitimate option • Procedural approach asserted in Colazal response is arbitrary and capricious under the law. 5 US

  52. Slide 52: Missing Legal Authority for In Vitro Method or BCS Guidance

    Missing Legal Authority for In Vitro Method or BCS Guidance • Once FDA engages in proper process for BE method development for Vancocin, it will also need to identify appropriate legal authority for whatever BE method is eventually adopted • The only authority currently cited for the new Vancocin in

  53. Slide 53: BCS Guidance Insufficient Legal Basis for New Vancocin BE Method

    BCS Guidance Insufficient Legal Basis for New Vancocin BE Method • Good Cause reg narrowly tailored to permit in vivo BE waiver only when necessary for “continued marketing of medically important drug products while adequate methodology is being developed or bioavailability studies are being conduct

  54. Slide 54: In Closing

    In Closing For an agent where a bioequivalence mistake could cause death, the Agency should: – engage in open process to ensure the highest quality BE science – return to clinical endpoint studies until a robust alternative method is developed ViroPharma is prepared to assist the Agency in a path fo

ViroPharma — SLIDE PRESENTATION on 6ix